no and i have been looking like crazy for the chemical make up of this. in a report a few years back, an analyst listed the schedule of compounds that clinuvel owns the rights to. havent had the time to check myself, but that would be a good starting point.  one thing i noticed in the recent patent grant from the USPO was the reference to NDP-MSH used in conjunction with another melanocortin.

yes i am a share holder, and have been in and out of this stock for years. a person can make decent money in sufficient volumes and patience. as far as long term, i have some IRA clvly shares if that is any indication.  I was taugh a long time ago to invest in what interests you and in things that ones self would purchase.  
 
I know a lot of people are frusterated at the sp and the lack of movement. Many believe this should skyrocket based on the progress and news, but most clinuvel investors ignore the simple facts too. fact is, this is in a brand new class of drugs that have not been seen by regulators. fact is this is an ADR traded on the pink sheets in tiny volumes, this is a fledgeling company with one drug, this is not an approved drug at this point, several self imposed deadlines have been missed, institutional investors are dropping like flies, there is not any major dealings with big pharma at this time... in short nothing is tangible with this stock. most investors are too close to this stock to face the reality this is a very high risk investment.  there are indicators mounting that this could happen, but still grossly outweighed by the cons.  
 
EPP approval will gain public interest, but the real money will only happen in the case of PMLE or vitiligo. once these large indications are trialed and approved, product price will drop and off label use will begin. sky is the limit from there. i will not speculate on future share price, but how many investments really see gains of hundreds of percents??  $ 1.00 ($10 in ADR) would be a 500% gain for me.. the rest is gravy.
 
and no im am not a chemist, but have some training. literally hundreds of hours of research on this drug have led to my long term commitment.  

Big_ Jake
 
You say the big money is in PMLE and Vitiligo once these large indications  
have been trialed and approved. My question is what have Clinuvel/ Epitan been trialing over the last 10 plus years.
 
In 2003 Epitan reported outstanding results with their phase 11b clinical trials and  
the results represented a massive step towards commercial development but now the emphasis is on EPP and possible vitiligo. What indications were they testing 7 years ago?
 
My belief was this drug was intended  for fair skinned individuals to help reduced sunburn and most importantly skin cancer which accounts for millions of people worldwide.  

Anyone know what is the earliest date and also the more probably date of CUV9900 being approved for use?  
(e.g., 3Q2011 best case scenario, 1Q2012 more probable ?)
 
I read that CUV9900 is currently in Phase III trials and that'll end in 1Q2011 and "Clinuvel will file its first regulatory submission to the European Medicines Agency (EMA) in second quarter 2011 on the basis of the results from three EPP studies: CUV017, CUV029 and CUV030." -  quoted from realpennies website.

Quote from Ferrara on 10/31/10 at 19:46:30:

 
 
Hello, Clinuvel has had nothing to do with ivy nanoparticles. All they've done is added a link to the following story:
 
http://www.cosmeticsdesign-europe.com/Formulation-Science/Nanoparticles-from-Eng lish-ivy-protect-against-UV
 
-Scott